Table 2.
Hip fracture | Major osteoporotic fracture | |||
---|---|---|---|---|
Modela | n | AUC (95% CI) | n | AUC (95% CI) |
All participants | ||||
Age | 92,075 | 77.1 (76.0–78.2) | 94,413 | 64.7 (64.1–65.2) |
Age + BMI | 92,075 | 77.4 (76.3–78.4) | 94,413 | 64.6 (64.1–65.2) |
Age + history of fracture (any site) | 92,075 | 77.1 (76.1–78.2) | 94,413 | 65.2 (64.6–65.7) |
FRAX alone (all participants) | 92,075 | 76.2 (75.1–77.3) | 94,413 | 65.0 (64.5–65.6) |
FRAX alone (white participants) | 79,909 | 75.4 (74.3–76.6) | 81,947 | 64.2 (63.6–64.8) |
FRAX alone (black participants) | 6194 | 81.2 (74.5–88.0) | 6903 | 60.6 (57.5–63.7) |
FRAX + treated diabetes | 92,075 | 76.5 (75.4–77.5) | 94,413 | 65.3 (64.8–65.9) |
FRAX + ≥2 falls in the past year | 92,075 | 75.4 (74.3–76.5) | 94,413 | 65.3 (64.8–65.9) |
FRAX + vasomotor symptoms | 92,075 | 74.8 (73.6–76.0) | 94,413 | 65.0 (64.4–65.5) |
FRAX + physical function | 92,075 | 75.9 (74.9–77.0) | 94,413 | 66.2 (65.6–66.7) |
FRAX + all additional factors | 92,075 | 76.2 (75.1–77.3) | 94,413 | 66.6 (66.0–67.1) |
BMD subset | ||||
Age | 5541 | 76.1 (72.1–80.2) | 5722 | 66.2 (64.1–68.3) |
Age + BMI | 5541 | 76.3 (72.2–80.4) | 5722 | 66.2 (64.1–68.3) |
Age + history of fracture (any site) | 5541 | 76.4 (72.5–80.4) | 5722 | 67.4 (65.3–69.5) |
FRAX alone (all participants) | 5541 | 77.6 (73.7–81.5) | 5722 | 69.8 (67.8–71.8) |
FRAX alone (white participants) | 4537 | 77.0 (72.8–81.1) | 4695 | 68.3 (66.1–70.5) |
FRAX alone (black participants) | 663 | 84.5 (69.2–99.9) | 672 | 65.6 (55.6–75.6) |
FRAX + treated diabetes | 5541 | 77.2 (73.1–81.2) | 5722 | 70.2 (68.2–72.1) |
FRAX + ≥2 falls in the past year | 5541 | 76.6 (72.6–80.7) | 5722 | 70.0 (68.0–72.0) |
FRAX + vasomotor symptoms | 5541 | 76.4 (72.1–80.7) | 5722 | 69.8 (67.8–71.8) |
FRAX + physical function | 5541 | 77.3 (73.4–81.2) | 5722 | 70.7 (68.7–72.7) |
FRAX + lumbar spine BMD | 5541 | 75.9 (71.7–80.1) | 5722 | 70.0 (68.0–71.9) |
FRAX + all additional factors | 5541 | 77.7 (73.4–81.9) | 5722 | 71.4 (69.4–73.4) |
All models are adjusted for intervention assignment in the WHI Hormone (Active, Placebo, not Randomized) and Calcium Vitamin D (Active, Placebo, Not Randomized) trials.